Hypertension in adult Fabry's disease: Is cardiotrophin-1 a diagnostic biomarker?

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cardiotrophin-1 (CT-1), a cytokine produced by cardiomyocytes and non-cardiomyocytes in conditions of stress, can be used as a biomarker of left ventricular hypertrophy and dysfunction in hypertensive patients. Hypertension is one of the main adverse events in the third and last phase of Fabry's disease (FD). We measured CT-1 in order to examine its correlation with the vascular and cardiac alterations at different ages and assess its potential for use as a biomarker of hypertension in FD. Findings: The level of CT-1 was clearly higher in hypertensive adults than in adult FD patients. FD patients show a small, non-significant decrease in plasma CT-1 with age, while in hypertensive patients CT-1 in plasma rises strongly and highly significantly with age. Conclusions: CT-1 can be considered a good biomarker of the progression of hypertension with age, but particular care is needed when following hypertension in FD patients, since CT-1 does not correlate the same way with this disease.

Cite

CITATION STYLE

APA

Marazzi, M. G., Galliera, E., Vianello, E., Dozio, E., Stella, A., Tettamanti, G., … Corsi Romanelli, M. M. (2014). Hypertension in adult Fabry’s disease: Is cardiotrophin-1 a diagnostic biomarker? Immunity and Ageing, 11(1). https://doi.org/10.1186/s12979-014-0027-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free